4.7 Article

Multiomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs

Journal

JCI INSIGHT
Volume 5, Issue 17, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.136477

Keywords

-

Funding

  1. National Natural Science Foundation of China [31871264, 31970569]
  2. Innovative Talent Promotion Plan of Shaanxi Province for Young Sci-Tech New Star [2018KJXX-010]
  3. Zhejiang Provincial Natural Science Foundation of China [LGF18C060002]
  4. Natural Science Basic Research Program Shaanxi Province [2019JM-119]
  5. Natural Science Foundation of Zhejiang Province [LWY20H060001]
  6. Fundamental Research Funds for the Central Universities

Ask authors/readers for more resources

More than 90% of autoimmune-associated variants are located in noncoding regions, leading to challenges in deciphering the underlying causal roles of functional variants and genes and biological mechanisms. Therefore, to reduce the gap between traditional genetic findings and mechanistic understanding of disease etiologies and clinical drug development, it is important to translate systematically the regulatory mechanisms underlying noncoding variants. Here, we prioritized functional noncoding SNPs with regulatory gene targets associated with 19 autoimmune diseases by incorporating hundreds of immune cell-specific multiomics data. The prioritized SNPs are associated with transcription factor (TF) binding, histone modification, or chromatin accessibility, indicating their allele-specific regulatory roles. Their target genes are significantly enriched in immunologically related pathways and other known immunologically related functions. We found that 90.1% of target genes are regulated by distal SNPs involving several TFs (e.g., the DNA-binding protein CCCTC-binding factor [CTCF]), suggesting the importance of long-range chromatin interaction in autoimmune diseases. Moreover, we predicted potential drug targets for autoimmune diseases, including 2 genes (NFKB1 and SH2B3) with known drug indications on other diseases, highlighting their potential drug repurposing opportunities. Taken together, these findings may provide useful information for future experimental follow-up and drug applications on autoimmune diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available